Stock listing

Xetra:PSH0 Sernova Biotherapeutics Inc Aktie

German listing (Xetra) of Sernova Biotherapeutics Inc · home listing TSX:SVA

Follow Sernova Biotherapeutics Inc into a list and get an email when it puts out news.

Share price · XETR:PSH0

€0.071 EUR +0.000 (+0.3%)

Close on Oct 27, 2026

Day range
€0.062 – €0.077 EUROct 27, 2026
Volume
16,855 sharesOct 27, 2026
Market cap
€26.81M EURAt the close on Oct 27, 2026 · price × 377.6M shares outstanding
Sernova Biotherapeutics Inc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TSX:SVA · Home$0.105 CAD-0.005 (-4.5%)47,270$0.105$0.105$0.105$0.110Close on Oct 30, 2026
OTC:SEOVF$0.08 USD-0.01 (-11.1%)28,800$0.07$0.08$0.07$0.09Close on Oct 27, 2026
Xetra:PSH0€0.071 EUR+0.000 (+0.3%)16,855€0.071€0.077€0.062€0.071Close on Oct 27, 2026
Ticker
Xetra:PSH0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Xetra
Currency
EUR

What changed lately

Latest news

Seraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post Merger BetaNova Biotherapeutics

Oct 19, 2026

Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

Oct 5, 2026

Sernova Biotherapeutics to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference

Sep 25, 2026

Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference

Sep 10, 2026

Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics

Sep 8, 2026

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Jun 17, 2026

Sernova Biotherapeutics Announces Closing of Recently Approved Financings

Apr 23, 2026

Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders

Apr 9, 2026

Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing

Mar 24, 2026

2026 Q1 MD&A

Mar 16, 2026

All Sernova Biotherapeutics Inc news

Financings

  • Convertible notes and common stock purchase warrants of Seraxis

    Oct 5, 2026

    Closed: US$11.2M raised

    Buyers: Dr. Steven Sangha / Arlo Investments; Jonathan Rigby; Will Rust

    Insiders: Insiders participated, including Dr. Steven Sangha / Arlo Investments, Sernova management and Seraxis management

    Use of proceeds: cGMP manufacturing of SR-02 islet cells and enrollment of T1D patients for the Phase 1/2 clinical trial

    Announced Sep 8, 2026 · Closed Oct 5, 2026

Read by 6ix AI from the company's releases

Decks

Sernova Biotherapeutics Inc on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 165 in all · newest Oct 19, 2026 · oldest 2015
Decks
13 decks · latest 2026

Where Sernova Biotherapeutics Inc is listed

ListingExchangeCountryCurrency
TSX:SVA · Home listingTSXCanadaCAD
OTC:SEOVFOTCUnited StatesUSD
Xetra:PSH0 · This pageXetraGermanyEUR
Tradegate:PSH0TradegateGermanyEUR
gettex:PSH0gettexGermanyEUR
Cboe Canada:SVACboe CanadaCanadaCAD
LS Exchange:A411DWLS ExchangeGermanyEUR
Lang & Schwarz:A411DWLang & SchwarzGermanyEUR
Munich:PSH0MunichGermanyEUR
Dusseldorf:PSH0DusseldorfGermanyEUR
Hamburg:PSH0HamburgGermanyEUR
Stuttgart:PSH0StuttgartGermanyEUR
Frankfurt:PSH0FrankfurtGermanyEUR
Hanover:PSH0HanoverGermanyEUR

Log in to ask 6ix AI your own questions about Sernova Biotherapeutics Inc.